Mike Madarasz, @MikeMadarasz
Cancer treatment has been revolutionized over the years and
much of that progress can be attributed to antibody therapeutics. However, not all antibodies are effective
therapeutics. They can instead be
utilized in antibody drug conjugates (ADCs) to deliver potent cancer-fighting
drugs. Tremendous progress has been made
in this field including steps to increase the therapeutic window. There are, however, improvements that can
still be made to increase the therapeutic qualities of these ADCs.
Here, authors from Genentech published a review article in the mAbs journal and describe the different strategies used
that are currently used in the creation of ADCs. Additionally, they summarize the differences
between methods and some of the crucial considerations in building next
generation ADC therapeutics.
Download the full report here
We’ve got more to
share about the latest in bioconjugates.
Check out Bioconjugates:
From Targets to Therapeutics to
hear more from top thought leaders including the team at Genentech.
June 4-6, San Francisco, CA.
Register Here
Discount Code:
D14199BLOG|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment